

# CFTR-RD Acute Recurrent or Chronic Pancreatitis

Aliye Uc, M.D.

Pediatric Gastroenterology

Hepatology, Pancreatology and Nutrition


#### Disclosures



Member of American Board of Pediatrics, Subboard of Pediatric Gastroenterology Consultant for Cystic Fibrosis Foundation

## CFTR gene






#### Mendelian Inheritance




#### How a Person Gets CF

To have CF, you must inherit two copies of the CFTR gene that contain mutations – one copy from each parent. That means that each parent must either have CF or be a carrier of a CFTR gene mutation.

When two people who are carriers have a child, there is a 25 percent chance of having a child with CF.



When one parent has CF and one parent is a carrier, there is a 50 percent chance of having a child with CF.






#### CF is Caused by Defects in CFTR Gene




- CFTR = Cystic Fibrosis
   Transmembrane conductance
   Regulator
- CFTR transports anions (Cl, HCO3)
- Active in epithelium of trachea/lungs, pancreas, intestine, sweat glands, bile ducts, vas deferens, etc
- Helps maintain proper fluidity and electrolyte composition of secretions




#### CFTR Channel-Functional






#### CFTR Channel-Defective










**CFTR** 


# Cystic Fibrosis





## Pancreas and Lungs in CF






- Early exocrine pancreatic insufficiency in majority; increased risk for ARP in pancreatic sufficient CF
- CF-related diabetes increases as patients age; adds to morbidity and mortality

## CF-Causing Mutations





## Testing for CF



- Newborn screening
- Sweat test-\*\*Gold standard
  - -<29 mmol/L-Normal
  - 30-59 mmol/L—Borderline or Intermediate
  - -> 60 mmol/L—Abnormal
- NPD
- Beta-adrenergic sweat test

# Diagnosis of CF



#### DIAGNOSTIC DEFINITIONS

Cystic Fibrosis

CF is diagnosed when an individual has both a clinical presentation of the disease and evidence of CFTR dysfunction.

Cystic Fibrosis
Related Metabolic
Syndrome (CRMS)/
Cystic Fibrosis
Screen Positive,
Inconclusive
Diagnosis (CFSPID)

Definitions for CRMS and CFSPID have been combined. CRMS/CFSPID applies to infants who have a positive NBS test for CF

#### AND either:

- A sweat chloride value <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences
   OR
- An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations

CFTR - Related Disorder A monosymptomatic clinical entity associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF



# Diagnosis of CF



#### **SWEAT CHLORIDE RANGES**

Diagnosis	≥ 60mmol/L	A positive newborn screen, clinical features consistent with CF, or a positive family history
Intermediate Range	30-59mmol/L	A positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in the intermediate range on two separate occasions may have CF. They should be considered for extended CFTR gene analysis and/or CFTR functional analysis.
Unlikely	≤ 29mmol/L	A positive newborn screen, and a sweat chloride of less than 30mmol/L indicates that CF is unlikely.  Clinical features that may be consistent with CF, a sweat chloride less than 30mmol/L, indicates that CF is less likely. It may however be considered if evolving clinical criteria and/or CFTR genotyping support CF and not an alternative diagnosis.



#### CFTR-RD



- Do not fit diagnostic criteria for CF (only monosymptomatic presentation such as ARP)
- Sweat Cl results are intermediate
- Genetic testing determines unknown CFTR mutations or CFTR genotype that is undefined (CFTR2 database)

# Take home points



- Patients with CF may present with recurrent pancreatitis
- Include Sweat Cl in work-up
- Look for other symptoms of CFTR dysfunction
- If diagnosed with CF, patients need to be followed by CF center

## Remaining Questions



- Are CFTR Mutations (non-CF causing) contributing to disease?
  - Impact on disease onset and progression
  - Interplay with other gene mutations and environmental factors to influence disease phenotype
- Would patients with CFTR-RD be candidates for CFTR modulator therapies?